LivzonDx Highlights Innovative Diagnostic Technologies at WHX Bangkok & WHX Labs Bangkok 2026

Time：2026-07-13

Bangkok, Thailand — WHX Bangkok & WHX Labs Bangkok 2026 has concluded successfully, gathering healthcare practitioners, laboratory experts, institutional buyers and medical technology enterprises across Thailand and Southeast Asia. During the three-day event held July 8–10, Zhuhai Livzon Diagnostics Inc. (LivzonDx) presented a selection of technology-driven in vitro diagnostic solutions at Booth H74, Queen Sirikit National Convention Center (QSNCC). The showcase featured blood-borned molecular diagnostics and automated chemiluminescence immunoassay solutions.

We exhibited our core flagship product lines and latest technological upgrades, delivering flexible, high-performance, clinically oriented IVD solutions tailored to evolving laboratory and public health demands across Southeast Asia.

High-Performance HIV-1 Viral Load Testing Took Center Stage for Clinical Treatment Monitoring

A primary highlight at our booth was the HIV-1 Viral Load RT-PCR Assay, engineered to support accurate HIV-1 diagnosis and standardized treatment monitoring. Co-developed with the Gates Foundation, the product is China's first ready-to-use lyophilized molecular reagent.

The assay adopted dual-target gene detection covering LTR and pol gene regions, which reduced false-negative risks stemming from viral genetic variation and delivered consistent, reliable detection results. Built-in internal control quantification eliminated extra reagent consumption, with ultra-high analytical sensitivity reaching 17.6 copies/mL. Its lyophilized format simplified laboratory workflows and cut operational costs, suiting routine clinical testing and large-scale public health screening to support local facilities with efficient, precise and sustainable HIV treatment management and therapeutic evaluation.

Specialized Autoimmune Diagnostics Powered by Automated CLIA Platforms

We displayed our mature benchtop chemiluminescence immunoassay systems — PATHVIZON i1900 and PATHVIZON i2900 — engineered to deliver flexible automated testing for specialized immunoassay and autoimmune diagnostic workflows.

The two models catered to labs with different testing throughput requirements. The compact PATHVIZON i1900 offered space-efficient benchtop testing for mid-to-small laboratories, while the high-capacity PATHVIZON i2900 addressed high-volume batch testing demands at large hospitals and central laboratories. Supported by an expanding reagent menu, the platforms supported testing across connective tissue diseases, rheumatoid arthritis, antiphospholipid syndrome, vasculitis, myositis, diabetes and tuberculosis TB-IGRA detection. Upcoming Alzheimer's disease biomarker assays pTau-217, pTau-181, GFAP, NfL, amyloid-beta 1-40 and amyloid-beta 1-42, were shared as pipeline innovations for future early neurodegeneration screening.

Diversified Portfolio Covering Infectious Disease Diagnosis and Transfusion Safety

Beyond core molecular and chemiluminescence product lines, we presented a full range of complementary diagnostic tools to support routine laboratory and public health work. The standout exclusive offering within this category was Serodia TP.PA, widely recognized as the global gold standard for syphilis serological testing, for which we have held exclusive global manufacturing rights since 2023. Alongside this flagship product, our team displayed physical lab samples including rapid blood grouping cards and BCI reagents.

The diversified product lineup addressed infectious disease confirmation, autoimmune screening and transfusion safety testing to meet varied specialized clinical laboratory requirements. The exhibition demonstrated our broad R&D footprint across molecular diagnosis, automated immunoassay and rapid testing, offering practical diagnostic tools to support daily lab operations throughout Thailand.

Productive Regional Exchanges Laid Groundwork for Future Win-Win Collaboration

Throughout the three-day exhibition, our team held in-depth, constructive discussions with hospital procurement managers, laboratory directors, research specialists and regional distributors from Thailand and neighboring Southeast Asian markets. These face-to-face dialogues delivered valuable insights into the latest trends and differentiated demands across Southeast Asia's diagnostic market.

We extend sincere gratitude to all visitors, partners and industry professionals who visited our booth and shared insights during the show.

Moving forward, we will continue centering our development on global clinical and public health priorities, steadily expand our multi-platform diagnostic product portfolio, and deliver more reliable, efficient and accessible diagnostic solutions to healthcare institutions and laboratory customers across Southeast Asia and globally.